Also, targeting the C5a/C5aR1 using the small molecule inhibitor avacopan has been approved for ANCA-associated vasculitis and is now frequently used in the clinic (41). Here, C5 is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.